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received hematopoietic stem cells (HSC) from the original
matched sibling cord blood donor, without additional preparative
therapy.Results/Outcome:Details of the 10 patients are provided
in the table. Cell doses for the ﬁrst and second HSC transplant
were not signiﬁcantly different. HSC for the second transplant
were 3 to 6 antigen matches (median  4). Median time interval
between the 2 transplants was 7 weeks (range 4–13). Five patients
died from TRM 2 to 6 weeks after second transplant without
engraftment. Three patients engrafted Neutrophils (days 14,
28, 36) after a second unrelated UCBT, but died from TRM
2.5 to 13 weeks after second transplant. Two patients with UCBT
from matched siblings did engraft following transplantation of
additional HSC. Conclusions: Graft failure following unrelated
UCBT proved to be fatal underscoring the critical reliance on
engraftment when the HSC donor is unavailable for a repeat
transplant. Although 3 patients engrafted after a second UCBT,
fatal infections and complications of GVHD still prevailed. Wead-
vise proceeding to a second transplant sooner than the 7 weeks in
our patients as the shorter duration of aplasia might improve the
outcome (Table 1).
Table 1. Second Transplant for Graft Failure after UCBT
UCBT
no. 1
HSCT
no. 2 UCBT
Second HSCT
Source
Allo
PBSCT
Allo
BMT
N  10 10 7 1 2
Age at transplant
(mo)
23 25 24 15 31
Weight at
transplant (kg)
23.3 22 24 14.3 25
CD 34  cells/kg
 106
0.74 0.80 0.70 2.60 11.3
MNC/kg  108 0.47 0.76 0.59 2.9 1.6
Engraftment 0 5 3 1 1
Interval UCBT
to HSCT no. 2
(wks)
7 7 7 6
TRM, N 8 7 0 1
TRM, days post
HSCT no. 2
median (range)
34.5 (17–91) 40 (17–91) 0 21
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There is a signiﬁcant amount of morbidity and mortality follow-
ing myeloablative CBHCT (Gluckman et al, NEJM 1997; Rubin-
stein et al, NEJM 1998). RI conditioning may reduce regimen-
related mortality (RRM) and the late effects associated with
myeloablative regimens without increasing the risk of graft failure
in children and adolescents (Del Toro et al, BMT 2004). Engraft-
ment has been demonstrated in adult recipients with hematologic
malignancies following RI CBHCT (Chao et al, BBMT 2004). We
report the results in 22 pediatric recipients , 6 F:16 M, median age
6.5 years (0.4–21). Twenty-one received unrelated CBHC, with
HLA matching of 4/6 (n  14), 5/6 (n  5), 6/6 (n  2); 1 sibling
CBHC (6/6). Seventeen had malignant [HD (5), NHL (2), NB(4),
AML (2), MDS(3), CML (1)], and 5 had non-malignant [-thal (1),
HLH (2), WAS (1), SCD(1)] diseases. Poor-risk disease was de-
ﬁned as induction failure, PD, SD, CR3, and second allo HCT
(n  8). RI conditioning was ﬂudarabine-based (150–180 mg/m2)
with either busulfan (8 mg/kg)  rabbit ATG/alemtuzumab or
cyclophosphamide  etoposide/etoposide phosphate  ATG and
craniospinal radiation prophylaxis (n  1). GHVD prophylaxis:
tacrolimus and MMF (Osunkwo et al, BBMT 2004). Median TNC
count was 3.8  107/kg (0.92–10.82) and CD34 count was 2.2 
105/kg (0.34–6.95). The median day to WBC engraftment was
19.5 (1–47) and to platelet engraftment was 40 (6-170). Engraft-
ment was 72.7%. There were 6 primary graft failures (1 CML, 1
-Thal, 2 HLH, 1 MDS, and 1 AML). Of the 16 engrafted
patients, 15 achieved 90% or greater mixed-donor chimerism by
day 60. Five of 16 patients developed acute GVHD, with 3 devel-
oping grade III/IV acute GVHD. One patient developed extensive
chronic GVHD. There were 8 deaths (4 PD, 1RRM, 3 GVHD).
The probability of 3-year overall OS in all patients was 61%.
Despite a log less nucleated cells/kg with CB versus PB or BM
HCT, the 3-year OS in standard-risk malignancy pts was 90%.
The 1-yearr OS in poor-risk malignancy pts was 21%. The 1-yearr
OS in non-malignant diseases was 75%. In conclusion, RI Allo
CBHCT may result in more rapid hematopoietic reconstitution
while decreasing RRM compared to myeloablative CBHCT and
may be associated with high mixed-donor chimerism. Patients with
diseases such as CML, -Thal, and HLH may require increased
intensity of conditioning. Further follow-up is required to evaluate
the long-term effects following RI Allo CBHCT.
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Between September 1998 and June 2005, 15 children, ages 12–59
months, underwent (UCBT) for treatment MPS III (Sanﬁlippo
Syndrome, types A or B). Grafts were mismatched at 0 (n  1), 1
(n  10), or 2 (n  4) HLA loci. Preparative regimen consisted of
busulfan 40 mg/m 2/dose PO or 1 mg/kg/dose IV targeting a Css
of 600–900 ng/ml), cyclophosphamide 50 mg/kg per day  4, and
equine ATG 30 mg/kg per day  3. Cyclosporine and solumedrol
were used as GvHD prophylaxis. Donor engraftment occurred in
10/15 patients, although one additional patient engrafted after a
second transplant. Five patients with graft failure died within 8
months of transplant due to respiratory failure and viral infections
(Adenovirus, HSV), and one died 2.9 years post UCBT after
complications of GvHD. Six patients developed mild to moderate
acute GvHD and 3 patients had limited (2) or extensive (1) chronic
GvHD. All children were followed at baseline with brain auditory
evoked responses (BAER), head MRI, and neurodevelopmental
assessments. These were followed in surviving children every 6
months for 2 years and yearly thereafter. At initial evaluation, 10
children had abnormalities in BAER and all patients showed ab-
normalities in head MRI consisting of varying degrees of volume
loss that generally increased with age. EEGs were normal in 6/9
patients at pretransplant evaluation with the additional 3 demon-
strating generalized encephalopathy. These abnormal changes
were evident in 6/9 patients post transplant with 2 additional
patients developing epileptogenic activity. Two patients developed
hydrocephalus requiring VP shunt placement within 1 year of
transplant and 1 patient had subdural hematomas after minor head
trauma. Eight had mild to severe cognitive delay at the time of
transplantation. After transplant, 2 patients with mild delay con-
tinue to gain skills at a normal rate (follow-up 1.5–2.5 years, age
range 40–53 months at the last evaluation). Six patients have
stabilized at their pre-transplant level of functioning and 4 have
shown regression after transplantation. All patients, however, sleep
well, have improvement in behavior and general well being. We
conclude that UCBT stabilized neurocognitive function for at least
4 years at pre-transplant level in the majority of patients and
improved general well being of all surviving children with MPS III.
Effects of transplantation should be explored further in a larger
group of patients.
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